Multinational pharmaceutical companies to benefit from new China guidelines: analysts

China's State Council has released new guidelines on innovative drug pricing, which Citigroup analyst John Yung calls "the most significant" in a decade. The framework, published this month, aims to reward drug innovation and ease pricing tensions for both domestic and multinational pharmaceutical companies. It supports value-based pricing for patented innovative drugs, allowing biotech firms to charge higher prices in private markets such as private hospitals, retail pharmacies, and online platforms. Meanwhile, generic drug prices will be driven down through market competition and volume-based procurement, where the government buys drugs in bulk for public hospitals, a move that has historically pressured multinationals.

The policy also calls for commercial insurance to play a larger role in funding innovative drugs, potentially creating more profitable channels for drugmakers. Yung noted this could benefit internet healthcare players, pharmacies, and private healthcare services, including Alibaba Health, Yifeng, and Hygeia. The guidelines signal China's commitment to fostering a robust, globally competitive domestic pharmaceutical industry, balancing innovation incentives with cost control in the public sector.